Glenmark Pharmaceuticals Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue increased to ₹3,433.80 Crore in Q2 FY2024, showing recovery from ₹3,207.38 Crore in Q1.
Net profit rebounded to ₹354.49 Crore in Q2 FY2024 after a loss of ₹61.56 Crore in Q1.
Operating profit margin improved to 12.61%, indicating better operational efficiency.

NEGATIVES

Q1 FY2024 saw a significant net loss of ₹61.56 Crore, raising concerns about profitability.
Operating profit declined sharply to ₹-124.35 Crore in Q1 FY2024, indicating operational challenges.
Revenue decreased by 6% from ₹3,401.60 Crore in Q1 FY2023 to ₹3,207.38 Crore in Q1 FY2024.

Field	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Jun 25
Revenue	3,401.60	3,207.38	2,506.70	3,062.95	3,244.19	3,433.80	3,387.55	3,264.44
Expenses	3,037.04	3,008.01	2,996.77	2,858.51	2,813.34	3,000.64	2,962.35	2,872.07
Operating Profit	364.56	199.37	-490.07	204.44	430.85	433.16	425.20	392.37
Other Income	20.87	1.70	45.41	773.16	31.49	39.42	31.13	26.44
Interest	112	121.46	134.34	148.56	39.58	48.48	52.29	58.23
Depreciation	154.65	141.45	147.07	151.34	117.79	120.28	122.74	129.93
Profit Before Tax	333.41	-124.35	-521.38	530.83	462.33	472.57	456.33	95.58
Tax	160.28	55.95	-71.80	1,769.47	122.10	118.09	108.30	48.61
Net Profit	173.13	-61.56	-330.81	-1,214.27	340.24	354.49	348.03	46.97
Eps in Rs	5.31	-2.90	-12.45	-43.17	12.06	12.55	12.33	1.66